Related Experiment Video

Updated: Aug 20, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

[Targeting of membrane receptor tyrosine kinases: is there resistance in the HER?]

Lucile Monnier1, Gérard Milano, Frédérique Penault-Llorca

  • 1Centre Alexis-Vautrin, Unité de biologie des tumeurs, EA3452, avenue de Bourgogne, 54511 Vandoeuvre-lès-Nancy Cedex.

Bulletin Du Cancer
|November 17, 2004
PubMed

Insights

Human Epidermal growth factor Receptors (HER) are key cancer targets. This review details resistance mechanisms to HER-targeted therapies, crucial for improving cancer treatment outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Human Epidermal growth factor Receptors (HER) are critical in cell growth and differentiation.
  • Overexpression of HER in tumors correlates with poor prognosis, making them significant cancer therapeutic targets.
  • Current therapies include monoclonal antibodies and tyrosine kinase inhibitors targeting HER signaling.

Purpose of the Study:

  • To review diverse mechanisms of resistance to anti-HER therapies.
  • To consolidate findings from preclinical and clinical studies on resistance pathways.
  • To provide insights into overcoming therapeutic challenges in HER-driven cancers.

Main Methods:

  • Literature review of preclinical and clinical studies on HER receptor signaling and resistance.
  • Analysis of identified non-specific and HER-specific resistance mechanisms.
  • Synthesis of information on pathway alterations, receptor interactions, and genetic factors.

Main Results:

  • Resistance mechanisms include PI3K/AKT pathway alterations and IGFR/VEGFR pathway recruitment.
  • Specific resistance involves MUC4 inhibition of antibody binding, HER heterodimerization, and mutated variants.
  • Genetic polymorphism and truncated soluble receptors also contribute to resistance.

Conclusions:

  • Understanding resistance mechanisms is vital for effective cancer treatment strategies.
  • Identifying these mechanisms can guide the development of novel therapeutic approaches.
  • Further research into resistance pathways will improve patient outcomes in HER-targeted cancer therapy.

More Related Videos

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...